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ABSTRACT:
Purpose. Benzimidazole class of compound is found to have diverse biological properties. From the literature
study, it is observed that depression is a severe mental disease affecting a huge population and pain is affecting
about 20% of world population. In continuation of our previous research work, we selected benzimidazole
pharmacophore to further explore its pharmacological activities. Methods. Forced swim test and Thermal
stimulus test were used to assess the antidepressant and analgesic activity of synthesized benzimidazole analogs.
Results. The antidepressant activity results showed that compound 3j was found most potent having Mean ±
SEM value 21.6 ± 0.8 for treated group. Furthermore, in the analgesic test, 3b, 3j, and 3o showed Mean ± SEM
values; 1.8 ± 0.10, 2.3 ± 0.10 and 2.2 ± 0.10, respectively. The study results suggested that these compounds
could be explored further for the development of better antidepressant and analgesic agents. Conclusion. From
the present study, it may be concluded that these active benzimidazole derivatives have been found to possess
potential antidepressant and analgesic activity.
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INTRODUCTION:
In the past years, there has been substantial interest in
the development and pharmacological activity of organic
compounds possessing hetero aromatic moiety in its
structure, such as benzimidazole [1,2]. Structurally,
benzimidazole core contains two aromatic N-
heterocycles that can bind to enzymes or receptors via
hydrogen bonds coordinated with metal ions or
hydrophobic interactions [3]. Classically,
benzimidazoles have been synthesized by the
Asian J. Pharm. Res. 2016; Vol. 6: Issue 3 [AJPRes.]
171
condensation of o-phenylenediamine with organic acids
or their analogs (nitriles, imidates, or orthoesters).
However, benzimidazoles can be synthesized under
oxidative cyclization by the cyclocondensation of o-
phenylenediamine with the corresponding aldehyde [4].
Benzimidazoles exhibit various pharmacological
activities such as antiparasitic, anticancer, antihistaminic,
antihypertensive and antiulcer [5]. Benzimidazole has
structural similarity to purine, and its analogs could
compete with purines [6]. Many benzimidazoles-
containing drugs such as thiabendazole (antiparasitic),
norastemizole (antihistaminic), telmisartan
(antihypertensive) and omeprazole (antiulcer) are used
widely to treat the said ailments [7, 8].
Depression is a state of low mood and the disinclination
of activity having a negative effect on a person’s
psychology, behavior, feelings, world view and physical
well-being. According to World Health Organization
data depression will be the second most disabling
condition in the world by the year 2020 [9]. The major
antidepressant drugs include: tricyclics, monoamine
oxidase (MAO) inhibitors, selective serotonin re-uptake
inhibitors, selective noradrenaline reuptake inhibitors,
serotonin modulators and norepinephrine serotonin
modulators [10].
Pain is an unpleasant sensation resulting from a harmful
sensory stimulation that alerts the body about current or
potential spoil to its tissues and organs [11]. Current
analgesic medications include opioids, non-steroidal
anti-inflammatory drugs (NSAID’s) and analgesic
adjuvants [12]. A number of new analgesics have been
introduced to the market to combat the challenge in the
treatment of pain like transient receptor potential
vanilloid type 1 (TRPV 1) channel, cannabinoid CB2
receptors, fatty acid amide hydrolase (FAAH) inhibitors,
GABAA subtype receptors and imidazoline I2 receptors.
These analgesic drugs either provide unsatisfactory pain
relief or result in dangerous side-effects [13]. From the
literature study, it can be concluded that benzimidazoles
act on various therapeutic targets such as
cyclooxygenase (COX) enzyme, transient receptor
potential vanilloid-1 (TRPV-1) ion channels,
cannabinoid receptors, bradykinin receptors, specific
cytokines and 5-lipoxygenase activating protein (FLAP)
etc [14]. The above-mentioned facts, prompt us to
develop the new structural prototype of benzimidazoles
for more effective and safer antidepressant and analgesic
agents.
We have earlier reported the anticonvulsant and toxicity
evaluation of the newer 1-{(1-(2-substituted benzyl)-1H-
benzo[d]imidazol-2-yl)methyl}-3-arylthioureas [15].
Inspired by the above- mentioned facts, we report herein
the antidepressant and analgesic activity of these
derivatives. Some of the benzimidazole-containing
marketed drugs are shown here (Figure 1).
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Figure 1. Structure of benzimidazole containing marketed drugs
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METHODS:
The synthesized benzimidazole analogs (Table 1) were
tested for their antidepressant and analgesic activity on
Swiss albino mice (20-25 g) of either sex. All the
animals used in the experiment were issued by the
Central Animal House Facility, Jamia Hamdard, and all
the methods used during the experiment were approved
by the Institutional Animal Ethics Committee Form no.
502 (173/CPCSEA, 28th Jan-2000). The animals were
kept under standard laboratory conditions (12 h light-
dark cycles); at an ambient temperature of 25 ± 20C and
relative humidity 50–60% in groups of six. They were
allowed free access to food (standard laboratory pellets)
and top water three days prior to the experiment.
Antidepressant Screening
The test compounds were screened by the method
described by Porsolt et al. [16]. Albino mice were placed
in a chamber (20 cm height; 45 cm in diameter)
containing water up to a height of 15 cm maintained at
25 ± 20C. The compounds to be tested were dissolved in
Tween 80 (0.2% w/v, 0.9% NaCl) and administrated by
ip route (100 mg/kg) 30 minutes prior the test session.
The period of immobility was measured during the 5-
minute test session as passive floating without
struggling, with only those movements that are necessary
to keep its head above the surface of the water.
Table 1. Chemical structure and Log P of test compounds
N
N
CH2
H2C
S C
NH
NHR1
R
Compound R R1 aLog P;
Found (calc.)
3b H 2-CH3C6H5 6.21(5.04)
3e H 2-OCH3C6H5 5.63(4.46)
3g H 4-OCH3C6H5 5.60(4.46)
3h H C10H7 6.70(5.71)
3j 2-Cl 2-CH3C6H5 6.73(5.75)
3l 2-Cl 4-CH3C6H5 6.68(5.75)
3m 2-Cl 2-OCH3C6H5 6.00(5.17)
3o 2-Cl 4-OCH3C6H5 5.57(5.17)
3p 2-Cl C10H7 7.12(6.42)
aLog P was determined by octanol: phosphate buffer method; Log P
was calculated using software ChemDraw Ultra 8.0.
Analgesic Screening
The synthesized compounds were screened for their
analgesic activity by the Thermal stimulus technique [17,
18] using mice. The animals were used in groups of 6
each and kept under standard laboratory conditions. Each
compound to be tested was administered orally (20
mg/kg) in the methyl cellulose-water (0.5% w/v)
mixture. The tail of mouse was gently dipped in
thermostatically controlled water maintained at 550C and
the analgesic activity was assessed after 4 h interval of
administration of the test drug. The end point observed
was the time that elapsed between immersion and the
attempt to withdraw the tail from hot water for control
group as well as the treated group of animals.
RESULT:
Antidepressant Screening:
Compounds (3b, 3e, 3g, 3h, 3j, 3l, 3m, 3o, and 3p) were
tested for antidepressant activity against the standard
fluoxetine at the dose level of 30 mg/kg. Antidepressant
activity was reported as mean average immobility time
in seconds. The data was analyzed by using students ‘t’
test and presented as Mean ± SEM data against the
individual untreated controls with the treated
compounds. Compound 3j showed an extremely
significant decrease in the immobility time (Table 2) and
was found potent with Mean ± SEM value 21.6 ± 0.8
comparable to Fluoxetine (23.7 ± 1.1) with extremely
significance level (p < 0.001). The compounds 3g and
3m were also found active with Mean ± SEM values
18.2 ± 0.4 and 23.4 ± 0.6; respectively with high
significance level (p < 0.001). Moreover, compounds 3e,
3l, and 3p also showed activity with Mean ± SEM values
36.4 ± 1.2, 30.5 ± 1.1, and 32.6 ± 1.2; respectively with
significance level having value (p < 0.05). The change in
the immobility time was found non-significant with
other compounds.
Table 2- Antidepressant activity of the compounds
Compound Mean average immobility time (s)a
Mean ± SEM
Control Treated
3b 38.4 ± 1.1 36.9 ± 1.3
3e 32.6 ± 0.8 36.4 ± 1.2*
3g 42.7 ± 1.0 18.2 ± 0.4**
3h 41.5 ± 0.9 38.8 ± 0.6
3j 30.6 ± 0.9 21.6 ± 0.8***
3l 35.6 ± 0.9 30.5 ± 1.1*
3m 28.6 ± 1.1 23.4 ± 0.6**
3o 42.8 ± 1.3 40.4 ± 1.2
3p 37.5 ± 0.8 32.6 ± 1.2*
Fluoxetine 42.5 ± 1.3 23.7 ± 1.1***
aDose = 30 mg/kg (p.o.); *p < 0.05, **p < 0.01, ***p < 0.001;  Data
was analyzed by unpaired students ‘t’ test.
Analgesic Screening:
The analgesic study was done on compounds (3b, 3e, 3g,
3h, 3j, 3l, 3m, 3o, and 3p) against the standard drug
diclofenac. The readings were noted as mean average
reaction time in seconds. The data was presented as
Mean ± SEM and the readings were analyzed by
students‘t’ test against the individual untreated controls
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with the treated compounds. Among the tested
compounds, 3b, 3j, and 3o were found to be most active
analgesics with Mean ± SEM values 1.8 ± 0.10, 2.3 ±
0.10 and 2.2 ± 0.10; respectively with highly significant
(p < 0.01) level. The compound 3e was found active with
Mean ± SEM value 1.1 ± 0.10 and found to be
significant (p < 0.05). Increase in the reaction time due
to other compounds was found to be non-significant
(Table 3).
LIPOPHILICITY DETERMINATION:
Drugs acting on the central nervous system have to cross
the blood-brain barrier (BBB) in order to show potency,
therefore, the therapeutic effect of such drugs has to be
correlated with optimum Log P which is near 2.
Theoretical Log P was calculated by using the software
ChemOffice 6.0 (Table 1). The experimental Log P
values were determined between octanol and phosphate
buffer at room temperature [19]. The theoretical Log P
values were compared with experimental values. In our
determination, the calculated Log P values were
correlated with CNS activity of the titled compounds,
showing dependence on biological activity. It was
observed that all the compounds are lipophilic in nature;
some of the values obtained from the experiment were
found to be in good agreement with the theoretical value.
Table 3 - Analgesic activity of the compounds
Compound Mean average immobility time (s)a
Mean ± SEM
Control Treated
3b 1.3 ± 0.10 1.8 ± 0.10**
3e 0.8 ± 0.10 1.1 ± 0.10*
3g 1.3 ± 0.10 1.3 ± 0.15
3h 1.2 ± 0.10 1.3 ± 0.21
3j 1.6 ± 0.15 2.3 ± 0.10**
3l 0.8 ± 0.10 1.0 ± 0.10
3m 1.2 ± 0.06 1.4 ± 0.10
3o 1.8 ± 0.10 2.2 ± 0.10**
3p 1.1 ± 0.06 1.3 ± 0.15
Diclofenac 1.4 ± 0.06 4.7 ± 0.10***
aDose = 20 mg/kg (p.o); *p < 0.05, **p < 0.01, ***p < 0.001; Data
was analyzed by unpaired students‘t’ test.
STRUCTURE-ACTIVITY RELATIONSHIP:
The structure-activity relationship study (Figure 2)
showed that the chloro group at the second position of
benzyl ring with 2-methyl phenyl substitution at
arylthioureas was found responsible for enhancing the
antidepressant potential. In the analgesic study, it was
found that the unsubstitution or the chloro substitution at
the second position of benzyl ring and 2-methyl phenyl
substitution at arylthioureas as well as the chloro
substitution at the second position of benzyl ring with 4-
methoxy phenyl substitution at arylthioureas were
enhancing the analgesic potential.
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Figure 2. Structure-activity relationship study of the potent compounds
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DISCUSSION:
Selected entries from benzimidazole series were
evaluated for their antidepressant and analgesic
activities. Compounds 3b, 3j, and 3o were found to
possess better CNS activity against standard drugs.
These compounds were found worthy of further
investigations aimed at assessing their CNS activity.
Currently, investigations are going on in our laboratory
in order to improve these findings by creating new
selective and potent molecules. Our findings will have a
good impact on chemists and biologists for further
investigation in search of benzimidazole derived
analgesics and antidepressants. Further studies are also
required to establish their mechanism of action.
ACKNOWLEDGEMENT:
One of the authors, Md Shamsher Alam, would like to
thank University Grant Commission (UGC), New Delhi,
for providing financial assistance.
REFERENCES:
1. Lednicer D. Strategies for organic drug synthesis and design. John
Wiley and sons, New York, 1998.
2. Katritzky AR, Tymoshenko DO, Monteux D, Vvedensky V,
Nikonov G, Cooper CB, Deshpande M. A new three-carbon
synthon for efficient synthesis of benzannelated and 1-(2-
arylethenyl) heterocycles. Journal of Organic Chemistry. 65; 2000:
8059-8062.
3. Wu L, Jiang Z, Shen J, Yi H, Zhan Y, Sha M, Wang Z, Xue S, Li
Z. Design, synthesis and biological evaluation of novel
benzimidazole-2-substituted phenyl or pyridine propyl ketene
derivatives as antitumour agents. European Journal of Medicinal
Chemistry. 114; 2016: 328-336.
4. Bui HTB, Ha QTK, Oh WK, Vo DD, Chau YNT, Tu CTK, Pham
EC, Thao Tran PT, Tran LT, Mai HV. Microwave assisted
synthesis and cytotoxic activity evaluations of new benzimidazole
derivatives. Tetrahedron Letter. 57; 2016: 887–891.
5. Bansal Y and Silakari O. The therapeutic journey of
benzimidazoles: A review. Bioorganic and Medicinal Chemistry.
2012: 6208–6236.
6. Fang X, Jeyakkumar P, Avula SR, Zhou Q, Zhou C. Design,
synthesis and biological evaluation of 5-fluorouracil-derived
benzimidazoles as novel type of potential antimicrobial agents.
Bioorganic Medicinal Chemistry Letter. 26; 2016: 2584–2588.
7. Li C, Tao X, Jiang J, Li X, Xiao S, Tao L, Zhou J, Zhang H, Xie
M, Zhu Y, Xia Z, Tang S, Yuan H, Li Q. Synthesis, crystal
structure and spectroscopic studies of bismuth(III) complex with
2-substituted benzimidazole ligands. doi:
10.1016/j.saa.2016.04.058
8. Dinparast L, Valizadeh H, Bahadori MB, Soltani S, Asghari B,
Rashidi M. Design, synthesis, α-glucosidase inhibitory activity,
molecular docking and QSAR studies of benzimidazole
derivatives. Journal of Molecular Structure. 1114; 2016: 84-94.
9. Kumar J, Chawla G, Akhtar M, Sahu K, Rathore V, Sahu S.
Design, synthesis and pharmacological evaluation of some novel
derivatives of 1-{[3-(furan-2-yl)-5-phenyl-4,5-dihydro-1,2-oxazol-
4-yl]methyl}-4-methylpiperazine.
http://dx.doi.org/10.1016/j.arabjc.2013.04.027
10. Prashanth MK, Revanasiddappa HD, Rai KML, Veeresh B.
Synthesis, characterization, antidepressant and antioxidant activity
of novel piperamides bearing piperidine and piperazine analogues.
Bioorganic and Medicinal Chemistry Letters. 22; 2012: 7065–
7070.
11. Since M, Freret T, Nee G, Terme T, Vanelle P, Boulouard M. New
orally effective 3-(2-nitro) phenylpropanamide analgesic
derivatives: Synthesis and antinociceptive evaluation. European
Journal of Medicinal Chemistry. 69; 2013: 728-734.
12. Lan Y, Chen Y, Xu X, Qiu Y, Liu S, Liu X, Liu B, Zhang G.
Synthesis and biological evaluation of a novel sigma-1 receptor
antagonist based on 3,4-dihydro-2(1H)-quinolinone scaffold as a
potential analgesic. European Journal of Medicinal Chemistry.79;
2014: 216-230.
13. Yan L, Pan M, Fu M, Wang J, Huang W, Qian H. Design,
synthesis and biological evaluation of novel analgesic agents
targeting both cyclooxygenase and TRPV1. Bioorganic Medicinal
Chemistry. 24; 2016: 849–857.
14. Siddiqui N and Alam MS. Anticonvulsant and toxicity evaluation
of newer 1-{(1-(2-substituted benzyl)-1H-benzo[d]imidazol-2-
yl)methyl}-3-arylthioureas. Der Pharma Chemica, 2(2); 2010:
163-171.
15. Gaba M, Singh S, Mohan C. Benzimidazole: An emerging scaffold
for analgesic and anti-inflammatory agents. European Journal of
Medicinal Chemistry. 76; 2014: 494-505.
16. Porsolt RD, Le Pichon M, Jalfre M. A new animal model sensitive
to antidepressant treatments. Nature. 266; 1977: 730-732.
17. Kendall DA, Browner M, Enna SJ. Comparison of antinociceptive
effect of gamma-aminobutyric acid (GABA) agonists: Evidence
for a cholinergic involvement. Journal of Pharmacology and
Experimental Therapeutics. 220; 1982: 482-487.
18. Jacob J and Blozovski M. Actions de divers analgesiques sur le
comportement de souris exposes a unstimulus thermoaigesique.
Archives Internationales de Pharmacodynamie et de Therapie. 3;
1961: 296-309.
19. Farrar VA, Ciechanowicz MR, Grochowski J, Serda P, Pilatia T,
Filippini G, Hinko CN, Assadi A, Moore JA, Edafiogho IO,
Andrews CW, Cory M, Nicholson JM, Scott KR. Synthesis and
cLog P correlation of imidoxy anticonvulsant. Journal of
Medicinal Chemistry. 36(23); 1993; DOI: 10.1021/jm00075a005.
